Flash Finance

Unichem Laboratories LimitedUNICHEMLABCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹510.55
MCap ₹3,595 Cr · P/E 11.8
Unichem Laboratories Limited — Stock analysis & AI research Unichem Laboratories Limited — Seasonality — best & worst months Unichem Laboratories Limited — Technical indicators & charts Unichem Laboratories Limited — Technical setup — score, trend, support & resistance Unichem Laboratories Limited — Live exchange announcements
📋 Low P/E Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results📋 High Promoter Holding Stocks 📈 Bollinger Squeeze Stocks📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹633 Cr
Sales · Jun 2026
+20.1% YoY
₹70 Cr
Operating Profit · Jun 2026
+211.0% YoY
11.1%
OPM % · Jun 2026
+158.1% YoY
₹41 Cr
Net Profit · Jun 2026
+496.1% YoY
₹5.89
EPS · Jun 2026
+495.3% YoY

📝 Unichem Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Unichem Laboratories Limited reported revenue of ₹633 crore for the quarter ended June 2026 (Q1 FY27), up 20.1% from ₹527 crore in the same quarter last year, and up 10.0% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹41 crore from a net loss of ₹10 crore a year earlier. Earnings per share (EPS) came in at ₹5.89.

Operating profit stood at ₹70 crore — an operating margin (OPM) of 11.1%, compared with 4.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Unichem Laboratories Limited posted revenue of ₹2,202 crore, a growth of 6.2% over FY25, with a net profit of ₹253 crore (up 74.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,308 crore with a net profit of ₹305 crore.

Valuation snapshot

At the current price of ₹510.55, UNICHEMLAB has a market capitalisation of ₹3,595 crore and a trailing P/E of about 11.8.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 15th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 70.22%, foreign institutional investors (FIIs) 2.70%, domestic institutional investors (DIIs) 9.40%, public shareholders 17.68% of Unichem Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹3,595 Cr
Current Price ?
₹510.6
P/E ?
11.80below ind
Industry P/E ?
37.20
P/B ?
1.32
P/S ?
1.56
P/FCF ?
22.05
Enterprise Value ?
₹4,095 Cr
EV/EBITDA ?
17.87
PEG ?
0.34
Earnings Yield ?
2.6%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹2,308 Cr
OPM ?
9.9%
Profit after tax (TTM) ?
₹305 Cr
EPS (TTM) ?
₹43.26
ROCE ?
4.0%
ROE ?
11.2%
ROA ?
8.2%
Growth
Sales — latest qtr ?
₹633 Cr
PAT — latest qtr ?
₹41 Cr
YoY qtr sales growth ?
20.1%
YoY qtr profit growth ?
496.1%
Sales growth (3y) ?
18%
Sales growth (5y) ?
12%
Profit growth (3y) ?
35%
Profit growth (5y) ?
24%
Financial Health
Debt ?
₹500 Cr
Debt to Equity ?
0.18
Interest Coverage ?
1.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
70.22%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-13.3%
Return 6 months ?
45.4%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 302402423416434432446507533587527579521575633 +20.1% +10.0%
Operating Profit -43162893825435586842266454870 +211.0% +45.7%
Other Income 16596116491497212871116 +128.9% +41.9%
Interest 466765457578797 +1.2% -26.4%
Depreciation 313029292827283231303231313130 -5.8% -3.4%
Profit Before Tax -61-472-2284-12615276258-9-112931949 +643.1% +157.8%
Net Profit -64-44-1-2484-1299255853-10-122641141 +496.1% +277.0%
EPS -9.08-6.28-0.09-3.4811.93-18.371.313.508.227.52-1.49-1.6937.541.555.89 +495.3% +280.0%
OPM % -14.1% 4.1% 6.6% 2.2% 8.8% 5.9% 9.7% 10.8% 16.0% 14.3% 4.3% 11.4% 8.6% 8.3% 11.1% +158.1% +33.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,074 Cr ₹2,202 Cr ₹2,308 Cr +6.2%
Operating Profit ₹268 Cr ₹182 Cr ₹229 Cr -32.1%
OPM % 12.91% 8.25% 9.93% -36.1%
NPM % 7.00% 11.48% 13.20% +64.0%
Other Income ₹36 Cr ₹326 Cr ₹335 Cr +811.8%
Depreciation ₹121 Cr ₹125 Cr ₹123 Cr +3.9%
Interest ₹21 Cr ₹31 Cr ₹31 Cr +44.9%
EBIT ₹147 Cr ₹56 Cr ₹106 Cr -61.7%
PBT ₹162 Cr ₹292 Cr ₹350 Cr +80.7%
Tax ₹15 Cr ₹3 Cr ₹9 Cr -82.8%
Net Profit ₹145 Cr ₹253 Cr ₹305 Cr +74.1%
EPS ₹20.55 ₹35.91 ₹43.29 +74.7%
Material Cost ₹756 Cr ₹501 Cr ₹490 Cr -33.7%
Employee Cost ₹297 Cr ₹208 Cr ₹203 Cr -30.0%
Extraordinary Items — ₹-334 Cr ₹-334 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14141414 +0.0%
Reserves 2,4212,4242,4372,703 +10.9%
Borrowings 314248460500 +8.7%
Other Liabilities 444589659520 -21.1%
Total Liabilities 3,1933,2753,5693,737 +4.7%
Fixed Assets 1,2571,2521,3001,213 -6.7%
CWIP 14712331100 +222.6%
Investments 2100 —
Other Assets 1,7871,8982,2392,425 +8.3%
Total Assets 3,1933,2753,5693,737 +4.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -8514-74 +157.1%
Cash from Investing Activity 24163-242192 +179.3%
Cash from Financing Activity -81-1061842 -98.9%
Net Cash Flow 75-29-65198 +404.6%
Free Cash Flow -1230-142163 +214.8%
CFO/OP 160%23%4%6% +50.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 160131135137 +1.5%
Inventory Days 414365418349 -16.5%
Days Payable 193174170128 -24.7%
Cash Conversion Cycle 382322382358 -6.3%
Working Capital Days 207173159169 +6.3%
ROCE % -5%-0%6%4% -33.3%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 70.22%70.22%70.22%70.22%70.22% +0.0%
FIIs 0.98%0.99%0.99%1.00%2.70% +170.0%
DIIs 10.92%10.74%10.73%10.63%9.40% -11.6%
Public 17.88%18.04%18.05%18.14%17.68% -2.5%
No. of Shareholders 23,01023,57723,26723,38626,164 +11.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Unichem Laboratories Limited's revenue in Q1 FY27?
Unichem Laboratories Limited reported revenue of ₹633 crore for the quarter ended June 2026 (Q1 FY27), up 20.1% from ₹527 crore in the same quarter last year, and up 10.0% sequentially over the March 2026 quarter.
What was Unichem Laboratories Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹41 crore from a net loss of ₹10 crore a year earlier. Earnings per share (EPS) came in at ₹5.89.
What is UNICHEMLAB's market capitalisation and P/E ratio?
At the current price of ₹510.55, UNICHEMLAB has a market capitalisation of ₹3,595 crore and a trailing P/E of about 11.8.
Who owns Unichem Laboratories Limited? (shareholding pattern)
As of Sep 2026, promoters held 70.22%, foreign institutional investors (FIIs) 2.70%, domestic institutional investors (DIIs) 9.40%, public shareholders 17.68% of Unichem Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI